Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zymeworks
Biotech
Former CBER chief Peter Marks leaps to Lilly—Chutes & Ladders
Former CBER chief Peter Marks leaps to Lilly. OSE swaps out CEO. Mikael Dolsten settles into board chair at cancer biotech.
Darren Incorvaia
,
Zoey Becker
Oct 10, 2025 8:30am
Zymeworks drops clinical-stage TCE over benefit-risk profile
Sep 2, 2025 8:10am
Galapagos CEO eyes exit as spinout names leader—Chutes & Ladders
Apr 25, 2025 8:30am
Zymeworks withholds one ADC from clinic in favor of another
Mar 6, 2025 10:25am
ASCO: Jazz shares 'unprecedented' biliary tract cancer data
Jun 1, 2024 11:11am
Zymeworks halts phase 2 ADC plans over 'clinical landscape'
Mar 7, 2024 9:00am
